Sunitinib vs everolimus (targeted agent versus targeted agent)
Health‐related quality of life · Treatment‐naïve metastatic renal cell carcinoma (any cell type)
1 finding from 1 review
- no estimate extracted1 study · 288 participantsLow
The review found no eligible studies for this question.
The review found no eligible studies for this question.
The review found no eligible studies for this question.